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BACKGROUND: Overall, B5% of patients show late normal-tissue damage after radiotherapy with a smaller number having a risk of
radiation-induced heart disease. Although the data are conflicting, large studies have shown increased risks of cardiovascular disease
(CVD) for irradiated patients compared with non-irradiated ones, or for those treated to the left breast or chest wall compared with
those treated to the right. Cutaneous telangiectasiae as late normal-tissue injury have so far only been regarded as a cosmetic burden.
METHODS: The relationship between late normal-tissue radiation injury phenotypes in 149 irradiated breast cancer patients and the
presence of cardiovascular disease were examined.
RESULTS: A statistically significant association between the presence of skin telangiectasiae and the long-term risk of CVD was shown in
these patients (P¼0.017; Fisher’s exact test).
INTERPRETATION:This association may represent initial evidence that telangiectasiae can be used as a marker of future radiation-induced
cardiac complications. It could also suggest a common biological pathway for the development of both telangiectasiae and CVD on
the basis of a genetically predisposed endothelium. To our knowledge this is the first reported study looking at this association.
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Virtually all breast cancer patients treated with breast conservation
and patients at high risk of recurrence after mastectomy receive
radiotherapy. The benefits of radiation therapy are not however
complication free. There is a wide spectrum of normal-tissue
reactions, and as life expectancy of cancer patients improves, these
are increasingly of clinical importance. Tissue toxicity may range
from asymptomatic changes in tissue structure and function, to
severe cosmetic disfigurement and life-altering changes in organ
function (Bentzen et al, 2003). The effects of radiotherapy can be
divided into early/acute or late, depending on whether they occur
within or after 90 days after radiation treatment (van der Kogel,
1993). Fibrosis, telangiectasiae and atrophy are examples of
common late normal-tissue manifestations (O’Sullivan and
Levin, 2003).
Radiotherapy substantially reduces the risk of local recurrence
after surgery, with a modest reduction in cancer mortality offset by
an increase in contralateral breast cancer and cardiac disease,
which is more marked in older trials. Many of the techniques used
involved some unavoidable irradiation of the heart leading to a
27% (95% confidence interval (CI) 13–41%) increase in mortality
from heart disease and reducing the beneficial effect of radio-
therapy on overall survival (Clarke et al, 2005). The cardiovascular
mortality risk in patients receiving radiotherapy for left-sided
breast cancer tends to become apparent after more than 10 years
of follow-up (Darby et al, 2003). It seems that this risk is side
and technique specific and is particularly associated with
irradiation of the internal mammary nodes (HR¼1.9, 95% CI
1.0–3.3) (Paszat et al, 2007). Evidence also exists of a significant
increase in the relative risk for myocardial infarction (MI) for
women who received adjuvant radiotherapy for left-sided com-
pared with right-sided lesions (Rutqvist and Johansson, 1990;
Paszat et al, 1998). All cardiac structures including the
pericardium, myocardium, valves, conduction system and cor-
onary arteries are amenable to radiation damage, and a common
pathophysiological pathway appears to be that of microcirculatory
damage (with the exception of valvular disease as valves are
avascular) (Stewart et al, 1995).
More recently, a greater number of patients received treatment
to the intact breast without parasternal internal mammary
node irradiation, which reduces the cardiac irradiated volume.
Although the cardiac dose from left-tangential radiotherapy has
also decreased considerably over the past few decades, part of the
heart still receives 420Gy for approximately half of those with
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sleft-sided tumours. The cardiac dose for right-sided patients is
generally from scattered irradiation alone (Taylor et al, 2008).
A wide range of additional risk factors have been associated with
an increased risk for cardiovascular morbidity and mortality after
breast cancer radiotherapy. These include irradiated heart volume
(Gyenes et al, 1997), total radiation dose (Gyenes et al, 1998) and
fractionation (Paszat et al, 1999), although the latter has not been
consistently shown (Marhin et al, 2007; Nilsson et al, 2009). There
seems to be an interaction between radiation-related cardiac
damage and cardiotoxic drugs such as anthracyclines (Bonneterre
et al, 2004), whereas acute cardiotoxicity following combination of
left-sided internal mammary chain irradiation and concurrent
trastuzumab use has not been clearly shown (Belkacemi et al, 2008;
Shaffer et al, 2009). A low overall incidence of cardiovascular
adverse effects has also been shown with the use of aromatase
inhibitors and tamoxifen (Mouridsen et al, 2007). In terms of
coexisting risk factors for developing radiation-induced heart
disease (RIHD), there is a significant interaction between pre-
existing hypertension, left-breast irradiation and the development
of coronary artery disease (Harris et al, 2006).
In an attempt to associate genotypes with phenotypes, our group
examined the relationship between late normal-tissue radiation
injury in breast cancer patients, early acute radiation reactions and
genotype (Giotopoulos et al, 2007). Patients were genotyped at
functional single nucleotide polymorphisms (SNPs) in various
candidate genes. As the power of genetic studies investigating the
genotype–phenotype correlations is absolutely dependent on the
precise definition of the phenotype, the Late Effects of Normal
Tissue-Subjective Objective Management Analytical (LENT-
SOMA) scale was used to evaluate radiation injury (Pavy et al,
1995). This scale provides both subjective and objective analyses
and a detailed and specific description of the nature (phenotype)
and severity of the injury(s) that are individually scored. Results
showed that homozygosity (TT) for the TGFb1 (C-509T) gene
promoter polymorphism confers a 15-fold increased risk of
fibrosis after radiotherapy (P¼3x10
 6) compared with (CC)
homozygotes, thus confirming previous independent analyses
(Quarmby et al, 2003; Andreassen et al, 2005). In addition, a
15Gy electron boost and/or the inheritance of X-ray repair cross-
complementing 1 (XRCC1) (R399Q) SNP contributed to the risk of
telangiectasiae. These data suggested distinct underlying genetic
and radiobiological pathways responsible for these side effects.
On the basis of the data from our previous study cohort, we
hypothesised a potential association between the presence of
cutaneous telangiectasiae as a late normal-tissue injury after
radiotherapy for breast cancer and an increase in the risk for
cardiovascular disease.
MATERIALS AND METHODS
Patients and methods
This report follows a previous study published by this group
(Giotopoulos et al, 2007). The study had been undertaken with the
participation of patients attending the breast cancer clinics in
Leicester Royal Infirmary and Glenfield Hospital, Leicester, UK.
The Oncology Department provides services for a population of
just below a million observing over 3500 new cases per year of
which 750 are newly diagnosed patients with breast cancer. All
patients with breast cancer having completed adjuvant treatment
are followed up annually for a minimum of 5 years.
Tumour-free breast cancer patients were sequentially recruited
by these breast cancer clinics. A total of 153 patients gave written
informed consent before entry into the study, and underwent an
examination of the affected area, and the recognised features of
late radiation effects were scored by the SOMA scale using sight
and/or palpation. Of these, fully completed questionnaires were
obtained for the majority of patients (n¼149) (Figure 1). All were
treated more than 4 years previously (median follow-up from time
of treatment for the entire group was 6.1 years). Radiotherapy
(6MV photons) was given either after mastectomy or wide local
excision (WLE) using tangential opposed fields. Initial surgery
was either a WLE with nodal sampling/clearance (n¼101) or
mastectomy (n¼45) plus axillary node dissection. Three patients
had inoperable tumours.
A variety of radiotherapy dose-fractionation schedules were
used (see Table 1). Two patients discontinued treatment early
because of unexpected severe acute reactions. All patients who
received an electron boost had a dose of 15Gy in five fractions in 1
week using 8–12MeV electrons to the tumour bed. The irradiated
area on these patients was similar (between 36 and 80cm
2).
Patients were asked about potential radiosensitising comorbid
diseases such as diabetes or collagen vascular disorders. They
also completed a questionnaire regarding cardiac symptoms and
diagnoses.
Cardiovascular disease (CVD) was defined by symptoms and
corresponding investigations that showed an abnormality in
cardiac function or structure. Vascular disease such as hyperten-
sion was not part of the CVD definition, although it was considered
as a risk factor for it. In this definition we included coronary artery
disease, atrial or ventricular dilatation, arrhythmias and congestive
cardiac failure. We excluded congenital heart disease or acquired/
secondary structural disease. Patients with known congenital
(cardiac shunts, previous corrective surgery or persisting structur-
al abnormalities such as valvular heart disease) or acquired/
secondary structural heart disease (rheumatic valve disease, mixed
Consented
n=153
Completed
questionnaire
n=149
Right-sided RTx
n=78
Left-sided RTx
n=71
T>1
n=18
T>1
n=15
T=1
n=2
T=0
n=54
CVD
n=5
CVD
n=1
CVD
n=3
Figure 1 Flowchart showing patients included in the analysis. CVD,
cardiovascular disease; RTx, radiation therapy; T, telangiectasia score.
Table 1 Summary of total radiotherapy doses including boost
Total No. of No. of
15-Gy electron boost
(No. of patients)
dose (Gy) fractions patients Boost No boost
34
a 17 1 1 0
38
a 17 1 1 0
40 15 9 1 8
45 20 111 65 46
50 25 27 0 27
Total¼149 Total¼68 Total¼81
aPatients who did not complete the planned radiotherapy schedule because of a
severe early reaction to radiotherapy.
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saortic valve disease, Coronary Artery Bypass Graft (CABG)) before
radiotherapy were excluded from the current analysis following a
detailed review of all available medical information by a
Consultant Cardiologist (GPM). Cardiovascular symptoms/diag-
noses were checked for all the recruited patients using a variety of
information systems within the University Hospitals Leicester,
which provide all secondary care assessment of patients with
known or suspected cardiac disease within Leicestershire. Patients
who had been investigated with an echocardiogram were high-
lighted within the Cardiac Investigations’ own record system and
the report obtained. The online radiology reports system was
screened to highlight any other relevant imaging such as cardiac
perfusion scans or coronary angiography. In addition, all patient
records on the Hospital Information Support System (HISS)
medical records/clinical coding system were examined to check for
clinical codes relating to cardiac diagnoses. All the medical
symptoms reported in oncology follow-up appointments were
reviewed using the electronic patient record system (MAISY –
Compucorp, Watford, Hertfordshire, UK). Death certificates of
deceased patients were obtained to check for causes of death
related to cardiac damage. Finally, any patient with a positive
finding in any of these modalities was investigated further with a
full review of their written medical records.
A total of fifteen patients with cardiac disease requiring referral
or investigations in secondary or tertiary care and who fulfilled
the inclusion criteria were identified. Six patients were excluded
on the basis of having pre-existing cardiac disease (Figure 2).
Two of these patients received left- and four received right-sided
radiotherapy. Reasons for exclusion included: cardiomegaly
and pulmonary congestion before radiotherapy treatment (one
patient), CABG pre-radiotherapy treatment (one patient),
rheumatic valve disease (one patient) and congenital heart disease
(three patients).
To assess whether the CVD patients (n¼9) had excessive heart
tissue irradiated, simulator planning films from all the patients
treated with left-sided radiotherapy were reviewed by three
investigators (RPS, JM, GAT). Accurately interpretable informa-
tion from planning films could only be obtained for 60 of the 71
left-sided patients. Of these, 42 patients had some cardiac outline
within the tangential field (defined as ‘in-field’) and 18 did not.
The heart in right-sided patients was automatically regarded as
‘out-of-treatment field’ (n¼78), thus giving an ‘out-of-field’
denominator of 96 and a total for the group of 138. The maximum
heart distance (MHD) was measured as a proxy for irradiated
volume with established level of agreement. The MHD was
measured between the posterior (mediolateral) field border to
the most distant heart contour in the beam’s-eye view of a
tangential treatment beam.
On the basis of the available information, the denominator
slightly differed between the analysis groups. Treatment side
information was available for 149 patients. The presence or
absence of telangiectasiae was recorded for 149 patients; however,
as 12 patients with a telangiectasia SOMA score of 1 were excluded
in an attempt to reduce inter-examiner bias, the analysis
denominator became 137 (see Results section).
Statistical analysis
The Fisher’s exact test was used to examine the relationship
between the various variables as well as the relationship between
phenotype and genotype. To test whether hypertension was an
independent risk factor, binary logistic regression was used. The
Statistical Package for the Social Sciences (SPSS 16.0, Chicago,
Illinois, USA) software package was used for the analysis.
Genotyping
A full description of the genotyping methods is included in our
previous paper (Giotopoulos et al, 2007).
RESULTS
Of the patients with available data (n¼149), 6% (9 of 149) were
identified as having cardiovascular disease between 3 and 12 years
after radiotherapy (mean¼6.6 years). Radiotherapy was given
after WLE (6 of 9), mastectomy (2 of 9) or biopsy (1 of 9). The
latter patient had an inoperable tumour.
Of the nine CVD patients (n¼9), three had no pre-existing
conditions or risk factors for cardiovascular disease. Four
patients had a history of hypertension, and three had received
anthracycline-based chemotherapy before radiation treatment
(Table 2). One of the patients had a reported history of myocardial
infarction 7 years pre-radiotherapy treatment. There was no other
confirmation of this patient’s MI apart from a single entry in the
medical records. As it may be particularly important to assess the
level of deterioration in patients with pre-existing ischaemic heart
disease rather than only include those who developed evidence
of cardiac-related symptoms after radiotherapy, we decided to
include this patient in our analysis.
All CVD patients had received left-sided radiotherapy (9 of 71)
at a mean age of 65 years, and in all but one (8 of 9) the heart was
within the tangential breast field (mean MHD¼1.9cm, median¼
0.56 and range 0–3.5cm). The following dose-fractionation
regimes were used: seven patients received 45Gy in 20 fractions
and two received 50Gy in 25 fractions.
The comparison between the CVD patient cohort in whom the
heart was within the radiation treatment field with the ‘out-of-field
group’ recorded an OR of 22.3 (95% CI 2.6–185.3) (Table 3). By
measuring the MHD, we had the advantage of showing that the
effects of radiation are more likely to be due to direct damage to
the heart rather than secondary to scattered irradiation. To test
whether MHD was a significant predictor of CVD in left-sided
patients, we carried out binary logistic regression, which showed
that MHD shows borderline significance (P¼0.056). There was no
association between the severity of telangiectasiae and MHD in the
CVD patient cohort (data not shown).
Five CVD patients who had been treated with WLE received a
15Gy boost (Table 2). As shown previously (Giotopoulos et al,
2007), the use of electron boost was associated with a higher risk of
telangiectasiae (Table 4). Dose per fraction (2 vs 42Gy) was not a
predictor for the development of CVD (data not shown). In
addition, our analysis did not show an association between
electron boost and the development of cardiovascular disease, as
this should not give significant additional dose to the heart
(Table 5). Although numbers limit the conclusions, there is some
Excluded CVD
patients
n=6
Right-sided RTx
n=4
Left-sided RTx
n=2
T>1
n=2
T>1
n=1
T=0
n=1
T=0
n=1
Figure 2 Flowchart showing excluded patients with documented
cardiovascular disease. One patient with a telangiectasia score of 1 is not
shown. CVD, cardiovascular disease; RTx, radiation therapy.
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spreliminary evidence that the predictive value of telangiectasiae is
higher in women not receiving a boost (data not shown). The use
of electron boost and hypofractionation was equal in left vs right
patients (Table 6).
A number of factors may influence the risk and severity of
late normal-tissue damage including chemotherapy or hormone
therapy. Analysis of the number of patients, who received
anthracycline-based adjuvant or neo-adjuvant chemotherapy
regimens, showed that this was not a significant predictor for
CVD in our data. There was also no association between the use
of adjuvant hormone therapy (tamoxifen) and the development
of CVD (data not shown).
Right- vs left-sided disease and CVD
A total of 149 patients were included in this group. All of the
identified patients with cardiovascular disease (9 of 9) had received
radiation treatment to the left side. When the left-sided cohort
was compared with the right-sided one (Table 3), a statis-
Table 2 Summary of patients (n¼9) with evidence of new CVD after radiation therapy
Patients with pre-existing
conditions or risk factors
for CVD (side/age at RTx) Indications Investigations Findings (years after RTx) RTx dose
1. None (L/69) SOB, palpitations ECG, ECHO, CT thorax Mild dilatation of RV and mild RV
function impairment (7)
45Gy in 20 fractions+boost
2. HT, anthracycline-based
chemotherapy (L/62)
SOBOE ECG,ECHO Borderline LVH, CCF (5) 45Gy in 20 fractions+boost
3. Treated SVT (L/58) Angina, MI at 5 years
post RTx
ECG, ECHO, cardiac
catheterisation, coronary
angiography
Mild LA dilatation, mild LAD and
diagonal branch disease (5)
45Gy in 20 fractions+boost
4. HT, anthracycline-based
chemotherapy (L/66)
Palpitations ECG, ECHO LV dysfunction, CCF and AF (4) 50Gy in 25 fractions
5. MI, anthracycline-based
chemotherapy (L/68)
SOBOE, syncope ECG, ECHO, myocardial
perfusion scan
Mildly impaired LV function, minor fixed
anterior ischaemia and possible fixed
inferior ischaemia (12)
45Gy in 20 fractions
6. HT, NIDDM (L/47) Palpitations ECG, ECHO Tachy-brady syndrome, AF (11) 45Gy in 20 fractions
7. None (L/69) SOB ECG, ECHO Borderline LA dilatation (8) 45Gy in 20 fractions+boost
8. HT (L/75) SOBOE ECG, ECHO Mild LA dilatation (3) 45Gy in 20 fractions+boost
9. None (L/78) SOB ECG, ECHO Mild LVH (5) 50Gy in 25 fractions
AF¼atrial fibrillation; CCF¼congestive cardiac failure; CVD¼cardiovascular disease; ECG¼electrocardiogram; ECHO¼echocardiogram; Gy¼Gray; HT¼hypertension;
LAD¼left anterior descending artery; LA¼left atrium; LVH¼left ventricular hypertrophy; MI¼myocardial infarction; NIDDM¼non-insulin dependent diabetes mellitus;
RTx¼radiation therapy; RV¼right ventricle; SOB¼shortness of breath; SOBOE¼shortness of breath on exertion; SVT¼supraventricular tachycardia.
Table 3 Summary of results
Cardiac disease
a
P-value
(test)
Odds ratio
(95% CI)
b
RTx Side (n¼149)
Left 9/71 0.001
(Fisher’s exact)
11.2 (1.3–90.6)
Right 0/78
Telangiectasiae 41( n¼137)
Yes (score 2–3) 5/32 0.017
(Fisher’s exact)
6.3 (1.4–28.5)
No (score 0) 3/105
Field (n¼138)
In 8/42 o0.001
(Fisher’s exact)
22.3 (2.6–185.3)
Out 1/96
‘In-field’ and telangiectasiae 41( n¼138)
Yes 5/12 o0.001
(Fisher’s exact)
29.3 (5.8–148.2)
No 3/126
CI¼confidence intervals; RTx¼radiation therapy.
aNumbers of patients with CVD
are calculated as complementary proportions of the total cohort.
bOn the basis of the
available information, the denominator slightly differs between the analysis groups.
Treatment side information was available for 149 patients. The presence or absence
of telangiectasiae was recorded for 149 patients; however, when patients with a
telangiectasia score of 1 were excluded in an attempt to reduce inter-examiner bias,
the analysis denominator became 137. Interpretable information through planning
films could be obtained for 60 left-sided patients. The heart in right-sided patients was
by definition considered as ‘out-of-treatment field’, thus giving an overall denominator
for the group of 138. All the CVD patients were included in these groups.
Table 4 Comparison of electron boost and telangiectasiae formation in
the entire cohort
Telangiectasia score 41( n¼32)
Yes No
Boost 21 41
No boost 11 64
Total¼137
P-value (test) 0.008 (w
2)
Twelve patients with a telangiectasia SOMA score of 1 (subtle, examiner-dependent
changes) were excluded from analysis, thus reducing the denominator from 149 to
137. Of the excluded 12 patients, six did and six didn’t receive an electron boost.
Table 5 Use of electron boost and CVD
CVD (n¼9)
Yes No
Boost 5 63
No boost 4 77
Total¼149
P-value (test) 0.73 (Fisher’s exact)
CVD¼cardiovascular disease.
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stically significant difference in the risk for CVD was recorded
(P¼0.001; Fisher’s exact test). When we carried out the exact same
comparison including all documented CVD patients (without
excluding patients with previous CVD), the association remained
significant (11 of 71 left-sided vs 4 of 78 right-sided patients;
P¼0.03).
Telangiectasiae and CVD
Presence or absence of telangiectasiae was documented for 149
patients. SOMA scores for telangiectasiae were analysed by
comparing affected (SOMA scores 2–3) and unaffected patients
(SOMA score 0). As in the previous study, SOMA scores of
1 (subtle, examiner-dependent changes) were excluded from
analysis to try and reduce inter-examiner bias. In this cohort,
12 patients had a telangiectasiae score of 1 (denominator used in
the analysis n¼137). Thirty-two patients developed telangiectasiae
SOMA score 41, of which 17 received right- and 15 received left-
sided breast irradiation. Five of the thirty-two (15.6%) patients
with telangiectasiae developed CVD, thus recording an OR of 6.3
(95% CI 1.4–28.0) when compared with 3 of 105 (2.9%) patients
with CVD in the non-telangiectasiae group (Table 3).
When we compared excluded plus included CVD patients
(without excluding any patients on the basis of pre-existing
structural or functional cardiac disease) who developed telangiec-
tasiae (SOMA score 41) (9 of 32) with the non-telangiectasiae
group (6 of 105), this recorded an OR of 6.4 (95% CI 2.1–19.9) and
a P-value of 0.004 (Fisher’s exact test).
Hypertension, smoking, diabetes and CVD
Pre-existing hypertension was reported in four of the five patients
with CVD and significant telangiectasiae (SOMA 41), although
this was not found to be an independent risk factor. To test this
further, binary logistic regression was performed. The model
contained hypertension, laterality and telangiectasia score. The
model as a whole explained between 18.8 and 30% of the variance
in risk for CVD and correctly classified 80.5% of cases.
Telangiectasia score was the only variable that made a statistically
significant contribution to the model recording an OR of 6.2 (95%
CI 1.1–36.2).
Of the entire cohort, 21% of the patients were current or ex-
smokers. None of the patients who developed CVD were smokers.
There was also no association between a pre-existing history of
diabetes and the development of CVD.
Comparison of well-established pre-existing cardiac disease risk
factors in left- vs right-sided patients showed no differences on the
basis of hypertension or age between the two groups. Smoking was
slightly more common in right-sided patients (Table 7).
Genotype–phenotype correlations
In this analysis, no association was observed between CVD and the
inheritance of alleles of the XRCC1 (R399Q) SNP, previously linked
to radiation-induced telangiectasiae, the fibrosis-associated TGFb1
(C-509T) gene promoter polymorphism (Giotopoulos et al, 2007)
or the eNOS (E298D) SNP that confers a weak protective effect
against radiotherapy-induced telangiectasiae (Giotopoulos et al,
2008).
DISCUSSION
Although radiotherapy has significantly increased the overall long-
term survival of breast cancer patients (Clarke et al, 2005), normal-
tissue radiation injury is increasingly becoming a factor that needs
to be taken into account particularly as it can affect quality of life.
In everyday clinical practice, there has also been an increasing
difficulty in estimating and counselling patients about the potential
adverse effects of radiation therapy and in particular their long-
term risk of RIHD. In an attempt to clarify some of these issues
and to assess whether there may be ways in identifying such high
risk patients, we analysed data from our cohort of patients. The
cardiac disease was confirmed using a variety of lines of enquiry
to reduce the possibility of failing to identify patients with such
diagnoses. Although we cannot say with certainty that no new
cardiovascular diagnoses were missed, there should be no bias
toward patients with left- and right-sided radiotherapy. Our
observations indicate a statistically significant association between
the long-term risk for CVD and the presence of cutaneous
telangiectasiae in this cohort.
Radiation-induced heart disease is thought to result from both
micro- and macrovasculature damage (Corn et al, 1990). The
damage to the microvascular component is initiated by endothelial
cell damage within cardiac structures. This is followed by
ischaemia, which seems to be secondary to capillary swelling and
progressive obstruction of the vessel lumen. The damaged area is
then replaced by fibrous tissue. Macrovascular damage results
from injury to larger vessels, leading to exacerbation of athero-
sclerotic lesion formation (Seddon et al, 2002). The most
important functional consequence is diffuse interstitial myocardial
fibrosis, which contributes primarily to diastolic dysfunction
(Gagliardi et al, 2001). In our analysis, we did not observe an
association between the common TGFb1 (C-509T) gene promoter
polymorphism known to significantly increase the risk for
radiation-induced fibrosis and CVD. However, it is possible that
other gene(s) in the same or different biological pathways may be
involved in the pathogenesis of radiation-induced myocardial
fibrosis. A recent study by Kuiper et al (2008) provides evidence
for a link between vascular damage and fibrosis. It was noted that a
shift in the balance between levels of the pro-angiogenic vascular
endothelial growth factor and the pro-inflammatory connective
tissue growth factor could explain the switch from angiogenesis to
fibrosis in patients with proliferative retinopathy.
For both left- and right-sided radiotherapy and with the use of
either tangential fields or intensity-modulated radiation therapy
Table 6 Use of electron boost and hypofractionation schemes in
patients receiving RTx to the left vs the right
RTx side
Electron Boost Left Right
Yes 36 32
No 35 46
Total¼149
P-value (test) 0.24 (w
2)
Dose per fraction (Gy)
21 4 1 4
425 7 6 4
Total¼149
P-value (test) 0.72 (w
2)
RTx¼radiation therapy; Gy¼Gray.
Table 7 Comparison of known pre-existing cardiac risk factors in left vs
right radiotherapy-treated patients
RTx side
Mean (year) age Hypertension Smoking
(n¼149) Yes No Yes Ex- No
Left 55.9 (s.d. 10.8) 10 61 7 2 58
Right 57.8 (s.d. 10.0) 7 71 12 10 52
P-value (test) 0.36 (Mann-Whitney) 0.33 (w
2) 0.04 (w
2)
SD¼standard deviation.
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s(IMRT), most of the heart receives 41Gy dose from scattered
irradiation (Li et al, 2000). This low-dose exposure of the whole
heart may contribute to the cardiac damage leading to increase in
cardiac mortality. Survivors of the atomic bombings in Hiroshima
and Nagasaki also showed evidence for this. They had received a
mean uniform single cardiac dose of p4Gy, and within this cohort
subsequent studies showed excess mortality from cardiac disease
(Preston et al, 2003). Another example is in men who have received
treatment for germ-cell tumours. Any chemotherapy or radio-
therapy to the para-aortic nodes or mediastinum in these
individuals increases their cardiovascular morbidity (van den
Belt-Dusebout et al, 2006).
It is interesting to note that in our cohort the CVD morbidity
was identified after left-sided irradiation only, in spite of cardiac
dose from treatment to the right side. Given the prevalence of CVD
in a population with a mean age of 65 years, this finding was
surprising as it is not entirely expected that only left-sided patients
would have developed post-radiotherapy CVD, unless solely
attributable to radiation, which seems unlikely. This may reflect
a relatively small cohort.
Our data could reflect that the presence of telangiectasiae might
be a better predictor for the development of cardiac disease than
traditional cardiovascular risk factors, and that the mechanism
precipitating this is different to that of atherosclerosis.
A number of additional factors may influence the risk and
severity of late normal-tissue damage. These include, but are not
limited to, the size and shape of the breast/chest wall, the type of
surgery and any complications, radiotherapy dose, fractionation
and time, adjuvant chemotherapy, whether the patient had a
severe, acute reaction and whether the individual patient was
genetically predisposed. The Standardisation of Breast radio-
therapy (START) B trial has recently shown that hypofractionating
regimes may not necessarily increase late effects (Bentzen et al,
2008). Chemotherapy may increase late effects (Fiets et al, 2003),
particularly anthracycline-containing regimens, but we did not
find a significant association between the two in our current
cohort. There was also no association between the use of adjuvant
hormone therapy (tamoxifen) and the development of CVD.
Telangiectasiae can develop at 6 months to many years after the
completion of radiotherapy and occur most often in the boost area
or the infra-mammary fold. Telangiectasiae are focal dilatations of
post-capillary venules mainly, but also occasionally of the
capillaries and arterioles of the subpapillary plexus (Requena
and Sangueza, 1997). They occur in an atrophic dermis under a
thin epidermis and present as areas of reddish discolouration
(Archambeau et al, 1995). The mechanisms by which telangiecta-
siae develop are not fully understood but they seem to be both
genetically and mechanistically predetermined. Their severity is
influenced by both treatment- and patient-related factors. There
are some fundamental radiobiological data describing macroscopic
and histological effects of chronic radiation damage using animal
models mainly rats (Trott, 1984). The primary effect of radiation is
DNA damage and there is evidence that the most vulnerable cells
are the endothelial cells. Models of telangiectasiae formation show
that impaired tissue microcirculation drainage leads to stasis in the
collecting venules, which results in the expansion of the capillaries
and venules characteristic of telangiectasiae. In our analysis, we
observed a statistically significant association between the long-
term risk for cardiovascular disease and the presence of cutaneous
telangiectasiae (Table 3). Interestingly, the significance of this
correlation was maintained and became even greater when we
included all the identified CVD patients with no exclusions.
Although telangiectasiae in most cases are only unsightly, our
findings could suggest a novel use as a marker and a predictor of
future cardiac-related complications. The early recognition of this
association may allow the clinician to modify the other cardiac risk
factors in these patients and therefore decrease their risk of
significant cardiac events. It could also have a function as a
screening tool for earlier diagnosis and treatment in this setting.
Previous studies have shown potential common genetic and
radiobiological pathways involved in the development of late
normal-tissue complications after radiotherapy (Quarmby et al,
2003; Andreassen et al, 2005; Giotopoulos et al, 2007). A potential
genotypic association between cutaneous telangiectasiae and the
development of RIHD would be intriguing as it may confer a number
of clinical implications. This would raise the question whether we
might be able to identify patients who should be recommended to
have partial breast irradiation and/or IMRT, or offer different
surgical options such as a mastectomy without radiotherapy.
Our conclusions are based on a relatively small cohort and
therefore these findings need to be replicated. There are a number
of potential confounders that we have not been able to assess
because of the design of the study, including body mass index and
a family history of cardiovascular disease. A potential problem is
that the cohort could have had an unexpected degree of subclinical
cardiovascular disease, although the lack of previously documen-
ted CVD events in the group receiving right-sided radiotherapy
mitigates against this. Although there was close consideration to
accurately define the inclusion criteria for CVD diagnoses, a
number of patients with additional cardiovascular events could
have been lost to follow-up. The significance of the association
between telangiectasiae and CVD was however maintained even
with or without exclusions for previous CVD. A possible source of
false association could be an undetected difference between the
groups receiving left- or right-sided treatment, but in this cohort
there was no difference in hypertension, telangiectasiae or other
variables except CVD. Smoking was slightly more common in
right-sided patients.
Our data show a statistically significant association between the
development of telangiectasiae as late normal-tissue injury after
radiotherapy and the risk for cardiovascular disease. The most
parsimonious explanation would be that a propensity for the
development of telangiectasiae and CVD are part of a common
biological pathway on the basis of a genetically predisposed
endothelium. If this conclusion is correct, we would expect
identification of genes that prove the association. Further studies
are required to explore the potential mechanisms and identifica-
tion of individuals at increased risk of RIHD to maintain a
reasonable therapeutic benefit for radiotherapy in breast cancer.
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